Industry News
SIA Action Agenda Newsletter
The Science Industry Australia (SIA) has released their latest newsletter 'Science Industry "Action"' in line with the launch of the Science Industry Action Agenda by the Commonwealth Government.
[ + ]Avastra shares slump below float price
Sydney-based biotechnology company Avastra (ASX: AVS) has turned in one of the poorest performances amongst recent biotech IPOs, after listing without fanfare earlier this week. In their Wednesday debut, Avastra shares dropped below their AUD$1.00 issue price to close at $0.85. At time of writing, they had slumped further to AUD$0.72. [ + ]
Imugene unveils details of piglet product
North Ryde animal-health biopharma Imugene Limited (ASX:IMU) is fast-tracking the commercialisation of its recently acquired receptor mimic technology (RMT). [ + ]
Anadis seals Tartura milk partnership
Melbourne biopharma Anadis (ASX:ANX) has signed an agreement with its long-time collaborator Tatura Milk Industries (TMI) that will secure its supply of antibody-rich colostrum from cows vaccinated with its patented vaccines. [ + ]
Sixth Ventracor device implanted
The sixth patient in Ventracor's (ASX:VCR) pilot trial has been implanted with the company's 'VentrAssist' left ventricular assistance device at The Alfred hospital in Melbourne. [ + ]
Prostate-of-the-art tomato
It’s deep red, juicy, tastes superb and should protect slightly less than 50 per cent of consumers against one of the most common of all cancers. And it’s not genetically modified. [ + ]
Sydney IVF produces stem cells
Fertility clinic Sydney IVF has obtained stem cells from an Australian embryo, which it will make available to stem cell researchers. [ + ]
Norwood Immunology aims to beat European IPO blues
Norwood Abbey Ltd [ASX:NAL NASDAQ:NABYF] is close to snatching victory from the jaws of a hostile London investment market, announcing today that its subsidiary Norwood Immunology will list next Wednesday on London’s Alternative Investment Market (AIM), selling 15 million shares and raising AUD$15 million. [ + ]
Horse hormones put athletes at risk
A Sydney endocrinologist says athletes who inject themselves with the illegal drug Equigen put their lives and careers at risk for no benefit. [ + ]
Biotron's Vpu blockers clear first hurdle
Canberra-based anti-viral drug developer Biotron has completed acute toxicity tests of its lead anti-HIV drug candidates in mice and found their toxicity levels are within acceptable limits. [ + ]
Bionomics presents new anti-angiogenesis evidence
Adelaide biotech Bionomics (ASX:BNO, BNOOA, US OTC:BMICY) will present new evidence for the therapeutic promise of several molecular antagonists for its proprietary drug target BNO69 in the US today. [ + ]
Downvalued Proteome Systems "cops it sweet"
North Ryde proteomics technology and research company Proteome Systems will list on the ASX later this year at a valuation of only $160 million, after sceptical fund managers baulked at a share price proposal that would have valued it at $300 million. [ + ]
Xenome gets IND green light and $2 million
The US Food and Drug Administration has approved Brisbane-based Xenome’s Investigational New Drug (IND) submission for its Xen2174 pain killer. [ + ]
Austcancer's Galenica acquisition finalised
Australian Cancer Technology ("AustCancer") (ASX:ACU) has finalised due diligence on its US$5 million acquisition of Alabama-based vaccine developer Galenica Pharmaceuticals. [ + ]
Innovation in the face of fire
The Cooperative Research Centre for Polymers (CRC-P) has won a CRC innovation award for the development and commercialisation of a polymer cable that will change fire protection around the world.
[ + ]
